Höskuldsdóttir, Gudrun
Franzén, Stefan
Eeg-Olofsson, Katarina
Eliasson, Björn
Funding for this research was provided by:
Västra Götalandsregionen
Sveriges Kommuner och Landsting
Merck
University of Gothenburg
Article History
Received: 22 November 2021
Accepted: 5 July 2022
First Online: 11 July 2022
Competing interests
: Professor Eliasson reports personal fees (expert panels, lectures) from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, NovoNordisk, RLS Global, and grants and personal fees from Sanofi, all outside the submitted work. Gudrun Höskuldsdóttir, Stefan Franzén and Katarina Eeg-Olofsson report no competing interests.